Patient, Oncologist, and Payer Preferences for Adjuvant Endocrine Therapy and CDK4/6 Inhibitor Regimens in Early-Stage Breast Cancer: A Discrete Choice Experiment.

Beusterien, Kathleen; Maculaitis, Martine C; Hallissey, Bernadette; Gaschler, Michael M; Smith, Mary Lou; Law, Ernest H

Beusterien, Kathleen; Maculaitis, Martine C; Hallissey, Bernadette; Gaschler, Michael M; Smith, Mary Lou; Law, Ernest H.

Afiliação

Beusterien K; Kantar, Health Division, Horsham, PA, USA.
Maculaitis MC; Kantar, Health Division, New York, NY, USA.
Hallissey B; Kantar, Health Division, Horsham, PA, USA.
Gaschler MM; Kantar, Health Division, New York, NY, USA.
Smith ML; Research Advocacy Network, Plano, TX, USA.
Law EH; Pfizer Oncology, Pfizer Inc, New York, NY, USA.

Patient Prefer Adherence ; 15: 611-623, 2021.

Article em En | MEDLINE | ID: mdl-33776424

Palavras-chave

cyclin-dependent kinase 4/6 inhibitors; endocrine therapy; stage II/III breast cancer; treatment preferences

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Idioma: En Ano de publicação: 2021 Tipo de documento: Article